Provided by Tiger Trade Technology Pte. Ltd.

NRX Pharmaceuticals Inc.

1.99
+0.08004.19%
Post-market: 2.000.0078+0.39%18:20 EST
Volume:469.08K
Turnover:911.06K
Market Cap:58.91M
PE:-0.86
High:2.00
Open:1.94
Low:1.82
Close:1.91
52wk High:3.84
52wk Low:1.58
Shares:29.61M
Float Shares:21.83M
Volume Ratio:0.70
T/O Rate:2.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3100
EPS(LYR):-2.3605
ROE:-682.61%
ROA:-97.83%
PB:-2.29
PE(LYR):-0.84

Loading ...

NRX Pharmaceuticals ernennt Joseph M. Casper zum Chief Operating Officer

Reuters
·
Feb 03

NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date

GlobeNewswire
·
Jan 16

NRX Pharmaceuticals Price Target Maintained With a $25.00/Share by BTIG

Dow Jones
·
Jan 15

NRX Pharmaceuticals Submits Real-World Data to FDA for Accelerated Approval of NRX-100

Reuters
·
Jan 14

NRX Pharmaceuticals (Nasdaq:Nrxp) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to Be Submitted to the FDA in Support of NRX-100 Approval

THOMSON REUTERS
·
Jan 14

NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 05

NRX Pharmaceuticals and neurocare Group Launch Nationwide Network for Integrated Mental Health Treatment

Reuters
·
Jan 05

NRX Pharmaceuticals Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Jan 02

NRX Pharmaceuticals Eliminates All Debt Through Equity Conversion

Reuters
·
Dec 30, 2025

NRX Pharmaceuticals Eliminates Remaining $5.4 Million Debt Through Equity Conversion, Achieves Debt-Free Balance Sheet

Reuters
·
Dec 18, 2025

NRX Pharmaceuticals Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
Dec 16, 2025

BRIEF-Nrx Pharmaceuticals Inc - Amends Ind Filing For Nrx-101 To Include Tms Use

Reuters
·
Dec 03, 2025

NRX Pharmaceuticals Inc - Amends Ind Filing for NRX-101 to Include Tms Use

THOMSON REUTERS
·
Dec 03, 2025

NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 02, 2025

NRX Pharmaceuticals Inc - Gdufa Goal Date Set for July 29, 2026

THOMSON REUTERS
·
Dec 02, 2025

NRX Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of Anda for Ketafree™, a Preservative-Free Iv Ketamine

THOMSON REUTERS
·
Dec 02, 2025

NRX Pharmaceuticals Inc - Applies for Ketafree as Proprietary Product Name

THOMSON REUTERS
·
Dec 02, 2025

FDA Accepts NRx Pharmaceuticals' ANDA for KETAFREE with Review Goal Date Set

Reuters
·
Dec 02, 2025

NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference

GlobeNewswire
·
Dec 01, 2025

Analysts Have Conflicting Sentiments on These Healthcare Companies: NRX Pharmaceuticals (NRXP), LifeMD (LFMD) and Hims & Hers Health (HIMS)

TIPRANKS
·
Nov 18, 2025